Skip to Content


National Cancer Institute; Notice of Closed Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, SBIR Topic 178—Chemical Diversity-Based Methods Identifying New Tumor Markers or Probes.

Date: March 13, 2000.

Time: 1 p.m. to 5 pm.

Agenda: To review and evaluate contract proposals.

Place: 6116 Executive Boulevard, Rockville, MD 20892, (Telephone Conference Call).

Contact Person: C.M. Kerwin, PhD, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of health, 6116 Executive Boulevard, Room 8086, Rockville, MD 20892-7405, 301/496-7421.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Start Signature

Dated: February 16, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 00-4301 Filed 2-23-00; 8:45 am]